混合弓部支架治疗急慢性主动脉病变:亚太多中心研究中期结果
NEOS-APAC 是亚太地区前瞻性多中心上市后研究,评估 E-vita OPEN NEO 行冰冻象鼻术治疗动脉瘤或夹层。112 例置入装置患者中,30 天死亡率为 1.8%,出院时技术成功率为 97.3%,3-6 个月治疗成功率达 95.0%,主要次要安全结局发生率低。
要点
- 30 天死亡率为 1.8%,180 天内全因死亡率为 3.6%,无死亡被评估为装置相关。
- 出院时技术成功率为 97.3%,3-6 个月治疗成功率为 95.0%。
- 3-6 个月主动脉相关死亡或破裂为 0%,装置完整性丧失为 0%。
核心结论
- NEOS-APAC 研究早期随访结果显示 30 天死亡率低、主要次要安全结局发生率低,与文献相比具有优势。
- 结果表明在亚太临床环境中使用 E-vita OPEN NEO 治疗安全有效。
研究设计与样本
- NEOS-APAC 为观察性、前瞻性、多中心上市后研究,在亚太地区评估 E-vita OPEN NEO 用于冰冻象鼻术治疗动脉瘤或夹层。
- 2021 年 8 月至 2024 年 2 月期间在 10 个亚太中心共入组 114 例患者,其中 112 例(平均年龄 59 ± 11 岁,81% 男性)接受装置置入。
- 98% 患者出院,90% 患者完成 3 至 6 个月随访;112 例患者分布于 3 种适应证:急性/亚急性主动脉夹层 34%/7%、慢性主动脉夹层 26%、胸主动脉瘤 33%。
主要发现
- 30 天死亡率(主要终点)为 1.8%,至 180 天全因死亡率为 3.6%,无死亡被评估为装置相关。
- 出院时技术成功率为 97.3%,3 至 6 个月治疗成功率为 95.0%。
- 3 至 6 个月主动脉相关死亡或破裂为 0%,装置完整性丧失为 0%。
- 至出院,新发致残性卒中 0.9%、新发截瘫 0.9%、新发轻截瘫 1.8%;至 3 至 6 个月,相应比例分别为 3.0%、2.0%、2.0%。
- 无患者发生肾衰竭。
临床怎么用
- 在亚太临床环境中,E-vita OPEN NEO 用于冰冻象鼻术治疗动脉瘤或夹层显示出安全的早期结局和良好的临床性能。
- 早期随访中 30 天死亡率及主动脉相关死亡/破裂、装置完整性丧失等主要次要安全结局发生率低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: NEOS-APAC is an observational, prospective, multicenter postmarket study in Asia-Pacific to demonstrate the safety and clinical performance of the E-vita OPEN NEO for frozen elephant trunk (FET) treatment of aneurysms or dissections. This article reports the first interim results until 3 to 6 months. METHODS: Overall, 114 patients were enrolled in 10 Asia-Pacific sites between August 2021 to February 2024. Among them, 112 (mean age 59 ± 11 years, 81% male) underwent device placement. Of these, 98% reached discharge and 90% 3 to 6 months follow-up. The E-vita OPEN NEO was implanted per treating physician discretion and per the instructions for use. The 112 patients were distributed among 3 different indications (34%/7% acute/subacute aortic dissection, 26% chronic aortic dissection, and 33% thoracic aortic aneurysm). RESULTS: The 30-day mortality (primary endpoint) was 1.8%, and all-cause mortality was 3.6% until 180 days. None of the deaths were evaluated as device-related. At discharge, technical success was achieved in 97.3%, and treatment success reached 95.0% at 3 to 6 months. Secondary endpoints included 0% aortic-related death or rupture and 0% loss of device integrity at 3 to 6 months. Until discharge, 0.9% patients experienced new disabling stroke, 0.9% experienced new paraplegia, and 1.8% new paraparesis, whereas until 3 to 6 months, the respective percentages were 3.0%, 2.0%, and 2.0%. No patients had renal failure. CONCLUSIONS: The NEOS-APAC study yields promising early follow-up results with a low 30-day mortality rate and low main secondary safety outcome rates, which compare favorably to literature. The results demonstrate safe and effective treatment with the E-vita OPEN NEO in the Asia-Pacific clinical setting.
引用
- Song SW, Park KH, Kim TH, et al. Hybrid Arch Stent Graft in the Treatment of Acute and Chronic Aortic Pathologies: Interim Results From an Asia-Pacific Multicenter Study. Ann Thorac Surg. 2026. PMID: 42744127. doi:10.1016/j.athoracsur.2026.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。